Literature DB >> 12093689

Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women.

Mayumi Nakagawa1, Raphael Viscidi, Ian Deshmukh, Maria Da Costa, Joel M Palefsky, Sepideh Farhat, Anna-Barbara Moscicki.   

Abstract

The time course of cell-mediated and humoral immune responses was elucidated in eight women with human papillomavirus type 16 (HPV-16) infection by performing serial HPV-16 E6 and E7 cytotoxic T-lymphocyte (CTL) assays and HPV-16 virus-like particle (VLP) antibody analyses. Four subjects had a single incident of HPV-16 DNA detection, and four subjects had two periods of HPV-16 DNA detection. In two of the women in the latter group, the second episode of HPV-16 detection occurred in the presence of high titers of HPV-16 VLP antibody, bringing into question the protective role of humoral immunity in preventing repeated infection. However, all four subjects rapidly became HPV-16 DNA negative following the second detection of HPV-16 DNA, suggesting the presence of immunological memory. In addition, one subject rapidly became negative for HPV-16 DNA despite having no evidence of CTL or VLP antibody response prior to the second HPV-16 DNA detection, suggesting the presence of immunological responses at an undetectable level. Overall, seven of eight subjects (88%) had detectable HPV-16 E6 and/or E7 CTL responses and seven of eight women (88%) had detectable HPV-16 VLP antibody responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12093689      PMCID: PMC120038          DOI: 10.1128/cdli.9.4.877-882.2002

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  39 in total

1.  HPV vaccine moves into late stage trials.

Authors:  H Connett
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

2.  NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16.

Authors:  D V Pastrana; W C Vass; D R Lowy; J T Schiller
Journal:  Virology       Date:  2001-01-05       Impact factor: 3.616

3.  Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females.

Authors:  A B Moscicki; N Hills; S Shiboski; K Powell; N Jay; E Hanson; S Miller; L Clayton; S Farhat; J Broering; T Darragh; J Palefsky
Journal:  JAMA       Date:  2001-06-20       Impact factor: 56.272

4.  Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma.

Authors:  Y Sun; J Eluf-Neto; F X Bosch; N Muñoz; J M Walboomers; C J Meijer; K V Shah; B Clayman; R P Viscidi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-10       Impact factor: 4.254

5.  Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.

Authors:  C D Harro; Y Y Pang; R B Roden; A Hildesheim; Z Wang; M J Reynolds; T C Mast; R Robinson; B R Murphy; R A Karron; J Dillner; J T Schiller; D R Lowy
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

6.  Lymphoproliferative response to fusion proteins of human papillomaviruses in patients with cervical intraepithelial neoplasia.

Authors:  H A Cubie; M Norval; L Crawford; L Banks; T Crook
Journal:  Epidemiol Infect       Date:  1989-12       Impact factor: 2.451

7.  Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles.

Authors:  R Kirnbauer; J Taub; H Greenstone; R Roden; M Dürst; L Gissmann; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

8.  Association of the antibodies against human papillomavirus 16 E4 and E7 proteins with cervical cancer positive for human papillomavirus DNA.

Authors:  T Onda; T Kanda; S Zanma; T Yasugi; S Watanabe; T Kawana; K Ueda; H Yoshikawa; Y Taketani; K Yoshiike
Journal:  Int J Cancer       Date:  1993-06-19       Impact factor: 7.396

9.  The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations.

Authors:  L Ho; S Y Chan; R D Burk; B C Das; K Fujinaga; J P Icenogle; T Kahn; N Kiviat; W Lancaster; P Mavromara-Nazos
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

10.  Identification of antibodies against human papillomavirus type 16 E6 and E7 proteins in sera of patients with cervical neoplasias.

Authors:  T Sasagawa; M Inoue; O Tanizawa; M Yutsudo; A Hakura
Journal:  Jpn J Cancer Res       Date:  1992-07
View more
  3 in total

1.  Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.

Authors:  Mark L Bagarazzi; Jian Yan; Matthew P Morrow; David B Weiner; Niranjan Y Sardesai; Xuefei Shen; R Lamar Parker; Jessica C Lee; Mary Giffear; Panyupa Pankhong; Amir S Khan; Kate E Broderick; Christine Knott; Feng Lin; Jean D Boyer; Ruxandra Draghia-Akli; C Jo White; J Joseph Kim
Journal:  Sci Transl Med       Date:  2012-10-10       Impact factor: 17.956

Review 2.  Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.

Authors:  Shreya Kanodia; Diane M Da Silva; W Martin Kast
Journal:  Int J Cancer       Date:  2008-01-15       Impact factor: 7.396

3.  A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.

Authors:  Alberto Monroy-García; Miguel A Gómez-Lim; Benny Weiss-Steider; Georgina Paz-de la Rosa; Jorge Hernández-Montes; Karyna Pérez-Saldaña; Yessica S Tapia-Guerrero; Mariel E Toledo-Guzmán; Edelmiro Santiago-Osorio; Héctor I Sanchez-Peña; María de Lourdes Mora-García
Journal:  Virol J       Date:  2011-02-09       Impact factor: 4.099

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.